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Letters to the Editor
“Super-Responders”
and “Hypo-Responders”
Neglecting the Obvious Question?
Hsu et al. (1) reported on the predictors of “super-response” (defined
y ejection fraction) to cardiac resynchronization therapy (CRT) and
he association with morbidity and mortality. By design, the study
equired paired echocardiographic studies (baseline and 12 months),
hich inevitably led to the exclusion of 337 (31%) patients random-
zed to CRT-D in the MADIT-CRT (Multicenter Automatic
efibrillator Implantation Trial with Cardiac Resynchronization
herapy) study (2). The authors rightly acknowledged the potential
or selection bias in favor of CRT, preferentially “selecting for a
uper-response group.” However, it is the exclusion of patients who
ay have perished within the first 12 months (perhaps due to adverse
esponse to CRT) that is of more concern, as the adverse effects of
RT may be well underestimated.
There were 74 deaths in the 1,089 patients (6.8%) randomized
o CRT in the MADIT-CRT study over an average follow-up of
.4 years (29 months) (2). This is comparable to the 53 deaths in
he 731 patients (7.3%) randomized to the implantable
ardioverter-defibrillator (ICD)-only group—an annualized mor-
ality rate of about 3%. There were 25 deaths in the subgroup of
52 patients in the current analysis by Hsu et al. (1). The majority
of deaths (48%) occurred in the “hypo-responders” (12 deaths in
190 hypo-responders, or 6.3%) over a median follow-up of 15.2
months following the 12-month echocardiographic study (i.e.,
from 12 to 27 months of follow-up)—almost double the annual-
ized mortality rate in the ICD-only group in the MADIT-CRT
study (assuming linear mortality rates).
However, even this doubling of mortality rates may have
underestimated the adverse effects of CRT in hypo-responders. By
the process of deduction, of the 74 deaths in the MADIT-CRT
study, only 25 deaths were accounted for in the current study (1).
Hence, the other 49 deaths must have occurred either in the 337
patients who were not included in the current analysis, and/or in
the last 2 months of follow-up (27 to 29 months) in the 752
patients included in the current study. That the majority of deaths
(49 of the 74 deaths) may have occurred in the minority of patients
(n  337) would infer either a much higher mortality rate among
hypo-responders (if the proportion of hypo-responders is similar inthe 337 patients) and/or a much higher proportion of hypo-
responders (if mortality rate among hypo-responders is similar to
the current report). I would urge the authors to present more data
on these deaths to clarify the risk of CRT among hypo-responders.
Finally, the data presented by Hsu et al. (1) indicate that
hypo-responders are more likely to have right bundle branch block
and shorter QRS duration (150 ms), which is consistent with
other published reports (3,4). As physicians compelled by the oath
of primum non nocere, and facing mounting evidence suggesting
limited benefit of CRT in patents with these characteristics (5),
should we not be asking the next obvious question: if there is no
evidence of benefit, is there evidence of harm?
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Reply
We appreciate the interest of Dr. Lim in our study of super-
response to cardiac resynchronization therapy involving patients
enrolled in the MADIT-CRT trial (Multicenter Automatic De-
fibrillator Implantation Trial with Cardiac Resynchronization
Therapy) (1). We thank him for his thoughtful review of our paper
and his inquiry involving overall mortality in our study.
Dr. Lim is correct that 74 of 1,089 patients (6.8%) randomized to
CRT died during an average follow-up of 29 months in the original
MADIT-CRT trial (2). In our sub-analysis (1), there were 25 deaths
in the subgroup of 752 patients (3.3%) studied over a median
follow-up of 15.2 months. However, Dr. Lim does not have access to
the primary data when he calculated crude mortality rates to draw
comparisons between hypo-responders from our study versus im-
plantable cardioverter-defibrillator (ICD) recipients from the original
MADIT-CRT trial. To clarify, in the ICD-only trial arm, 30 of 623
patients (4.8%) with left ventricular ejection fraction (LVEF) mea-
surements at both baseline and 12-month echocardiograms subse-
quently died, compared with 25 of 752 patients (3.3%) in our study of
CRT-D recipients. Therefore, to compare a crude mortality risk of
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CRT-D hypo-responder group and claim that hypo-responders had
“almost double the annualized mortality rate” is incorrect and statis-
tically unsound.
We do not agree with the statements of Dr. Lim that our study
“underestimated the adverse effects of CRT in ‘hypo-responders’”
or that the 49 deaths not accounted for in our cohort infers a
higher proportion/mortality rate of “hypo-responders.” We would
like to clarify any misunderstandings from the inferences of Dr.
Lim. Of the other 49 deaths in the CRT-D arm not included in
our analysis, 23 of 337 excluded patients (6.8%) died during the
first year of follow-up, and 26 of 337 excluded patients (7.7%) died
after the first year. By definition, the 337 excluded patients had
higher rates of death, because some patients died before or
otherwise did not meet the inclusion criteria of our cohort of both
baseline and 12-month follow-up echocardiograms. These data
indicate that patients who had not died but missed their 12-month
echocardiogram might be at greater risk of subsequent poor
outcomes, perhaps from factors associated with incomplete
follow-up (e.g., illness). Although selection bias might have been
introduced, we found no other feasible way to perform an analysis
with LVEF change, because serial LVEF measurements were
conditional on having survived to 1 year. We acknowledged this
potential limitation in our paper (1).
Finally, our study identified characteristics including left
bundle branch block and longer QRS duration (150 ms)
associated with super-response to CRT-D therapy, and thus we
agree with Dr. Lim that these findings highlight the possibility
that patients with the converse might not derive similar
benefits, despite incurring the risk and costs of this therapy.
However, to recommend withholding CRT-D therapy in a
subgroup of otherwise eligible patients without prospective
studies to support this practice might be ill-advised. As a result,
we believe that the hypotheses generated by these observations
should be tested in future studies.
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Absence of Cardiovascular
Implantable Electronic
Device Infection in
Remote Implantations
Demonstrated by Fluorine-18
Positron Emission Tomography
We read with strong interest the paper by Sarrazin et al. (1), which
reported on the utility of Fluorine-18 (18F-FDG) positron emission
omography (PET)/computed tomography (CT) for identification of
ardiovascular implantable electronic device (CIED) infections. As
oted in the article, the diagnosis of CIED infections can be very
hallenging, and unnecessary device extraction can expose the patient
o significant morbidity and mortality (2,3). The paper suggested a
igh sensitivity and specificity of 18F-FDG PET/CT in differentiat-
ing pocket and/or lead infections from non-infected devices older
than 6 months. However, the control group in the study was small
(only 10 patients), and the prevalence of increased nonspecific
18F-FDG uptake in not-infected CIED patients is unknown. To
urther validate the negative control, we decided to review 69
18F-FDG PET/CT scans performed on patients with remote im-
plantable cardioverter-defibrillator (ICD) insertion for elective rea-
sons. All patients with remote ICD insertion and no clinical/
laboratory evidence of infection undergoing 18F-FDG PET/CT in
reparation for ventricular tachycardia ablation from 2006 to 2011
ere identified in our institution. Semi-quantitative assessment of
18F-FDG uptake was assessed in 4 sites (generator pocked, innomi-
ate vein, superior vena cava, and intracardiac space [right atrium/
entricle]). Uptake was categorized in none (score  0), mild
thoracic background activity; score  1), moderate (thoracic
ackground activity; score  2), and severe hypermetabolism (very
ntense uptake; score  3). Evaluation of 69 contiguous patients
evealed 18F-FDG signal uptake scores of 0 in all segments. Thus, our
data further strengthens the validity of negative controls in the current
paper and supports a potential use of 18F-FDG PET/CT in differ-
entiating patients with CIED infection from chronic implant
changes, providing a new path in management of CIED infection.
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